- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05267665
Participación familiar en el tratamiento del PTSD (FIT-PTSD): un método breve y factible para mejorar los resultados, la retención y el compromiso
Although effective treatments for PTSD exist, high rates of treatment dropout and sub-optimal response rates remain common. Incorporating family members in treatment represents one avenue for improving outcomes and providing Veteran-centered care, and surveys of Veterans in outpatient VA PTSD care indicate that 80% desire family involvement. The VA has invested many years and millions of dollars on the dissemination of Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) for PTSD. A family-based intervention that complements these two first-line treatments would capitalize on existing treatment infrastructure while also potentially boosting outcomes and retention.
Preliminary testing of the proposed Brief Family Intervention (BFI) resulted in 50% less dropout from CPT/PE among Veterans whose family members received the BFI. There was also a large impact on PTSD symptoms at 16 weeks (d = 1.12) in favor of the BFI group. The goal of this study is to test the effectiveness of the BFI among a fully-powered sample. One hundred Veteran-family member dyads (n = 200) will be recruited. Veterans will be beginning a course of usual-care CPT or PE at one of two VA sites. Family members will be randomized to receive or not receive the BFI, a two-session psychoeducational and skills-based protocol. PTSD symptom severity and treatment retention will be the primary outcomes. Assessments will be conducted by independent evaluators at baseline, 6-, 12-, 18-, and 26-weeks. Veterans whose family members receive the BFI are expected to have lower dropout and a greater rate of change in their PTSD symptoms compared to Veterans whose family members do not receive the BFI. If the BFI is found to increase the effectiveness of and retention in CPT/PE, it will be a highly appealing option for incorporating families into Veterans' PTSD care.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Johanna Thompson-Hollands, PhD
- Número de teléfono: (857) 364-2067
- Correo electrónico: Johanna.Thompson-Hollands@va.gov
Copia de seguridad de contactos de estudio
- Nombre: Cameron Busser, BA
- Número de teléfono: (857) 364-4143
- Correo electrónico: cameron.busser@va.gov
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02130-4817
- Reclutamiento
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
-
Contacto:
- Johanna Thompson-Hollands, PhD
- Número de teléfono: (857) 364-2067
- Correo electrónico: Johanna.Thompson-Hollands@va.gov
-
Investigador principal:
- Johanna Thompson-Hollands, PhD
-
Contacto:
- Cameron Busser, BA
- Número de teléfono: (857) 364-4143
- Correo electrónico: cameron.busser@va.gov
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705-3875
- Reclutamiento
- Durham VA Medical Center, Durham, NC
-
Contacto:
- Nicole Pukay-Martin, PhD
- Número de teléfono: 17-7548 919-286-0411
- Correo electrónico: nicole.pukay-martin@va.gov
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45220
- Reclutamiento
- Cincinnati VA Medical Center, Cincinnati, OH
-
Contacto:
- Nicole Pukay-Martin, PhD
- Número de teléfono: 3251 513-861-3100
- Correo electrónico: nicole.pukay-martin@va.gov
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Inclusion criteria for Veterans will include:
-
a current DSM-5 diagnosis of PTSD
-
Veteran status
-
willing to have a family member involved in the study
-
has recently begun or is currently initiating individual CPT or PE (completed no more than 3 sessions of the protocol at the time of the baseline assessment)
- If taking psychotropic medication, the Veteran must be on a stable dose for at least 30 days.
Inclusion criteria for family members will include:
- age 18 or older, family member of the Veteran (significant other, parent, adult child, sibling, etc.)
- currently having frequent contact with the Veteran (three or more times per week)
Exclusion Criteria:
Exclusion criteria for Veterans will include:
- current engagement in couple/family treatment with the identified family member participant
- current severe substance use disorder (mild/moderate use disorders will not be excluded; any level of nicotine or caffeine use disorder accepted)
- current psychosis or unstable bipolar disorder diagnosis
- high suicidal risk
- significant cognitive impairment
Exclusion criteria for family members will include:
- same as listed for Veterans. Additionally
- family members will NOT be permitted to participate if they meet criteria for current PTSD
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: BFI
Family members in this arm receive the 2-session BFI intervention. |
A 2-session psychoeducational and skills-based family intervention. |
|
Sin intervención: No BFI
Family members in this arm do not receive the BFI sessions |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Periodo de tiempo: Week 26
|
Severity of PTSD symptoms. Minimum score is 0 (best possible, no symptoms) and maximum score is 80 (worst possible, highest symptoms). |
Week 26
|
|
Adequate treatment dose
Periodo de tiempo: Week 26
|
Categorical evaluation of whether the participant received 8 or more on-protocol sessions of CPT or PE during their 26-week study participation period. Possible scores are 0 (meaning <8 sessions received; this is considered a poor outcome) or 1 (meaning 8 or more sessions received; this is considered a good outcome). |
Week 26
|
|
Treatment dropout
Periodo de tiempo: Week 26
|
Categorical evaluation of whether the participant dropped out of treatment early. Possible scores are 0 (meaning participant did not drop out of treatment early; this is considered a good outcome) or 1 (meaning participant did drop out of treatment early; this is considered a poor outcome). |
Week 26
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Homework compliance
Periodo de tiempo: Week 26
|
Compliance with assigned homework during treatment. Minimum score is 0 (worst possible), maximum score is 150 (best possible). |
Week 26
|
|
Quality of Life Inventory (QOLI)
Periodo de tiempo: Week 26
|
Quality of life. Minimum score is -6 (worst possible), maximum score is 6 (best possible). |
Week 26
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Johanna Thompson-Hollands, PhD, VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- MHBP-005-21S
- 1I01CX002339-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
An anonymous dataset that meets VA standards for disclosure to the public will be made available within 1 year of publication. Prior to distributions, a privacy officer at the primary site will certify that all datasets contain no PHI. The PI will create a de-identified dataset that will include all publication variables. To remove some PHI, loss of information may occur. The PI will replace any identifiable information with study-specific numbers. Data collected on age will be replaced by the PI with age categories to ensure data is in accordance with PHI requirements for people 85 years of age and older (if applicable).
Marco de tiempo para compartir IPD
An anonymous dataset that meets VA standards for disclosure to the public will be made available within 1 year of publication. The data will be made available until the data is destroyed according to the required timelines in the VA Record Control Schedule.
Criterios de acceso compartido de IPD
Individual requesting access to the data will be required to complete an adequate Data Use Agreement.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .